肥胖与非肥胖非酒精性脂肪性肝病患者的循环脂质组学改变
该横断面分析纳入361例经活检证实的非酒精性脂肪性肝病(NAFLD)患者(157例非酒精性脂肪肝和138例非酒精性脂肪性肝炎)及66名健康对照,按亚洲体重指数切点分为肥胖与非肥胖,检测血清脂质组谱,并在独立验证集(154例NAFLD和21名健康对照)中验证。非肥胖与肥胖NAFLD患者具有独特的循环脂质组学特征,包括二酰甘油、三酰甘油和鞘磷脂,这些脂质组合可能作为有用的生物标志物。
要点
- 饱和鞘磷脂(SM)种类与非肥胖NAFLD患者的内脏脂肪堆积显著相关(SM d38:0;P < 0.001),但在肥胖NAFLD中无此关联。
- SM水平与全身及脂肪组织胰岛素抵抗显著相关(SM d38:0;P = 0.002和<0.001)。
- 分别选出5种(非肥胖)和7种(肥胖)潜在脂质代谢物预测NAFLD和NASH,诊断性能良好(非肥胖AUC 0.916/0.813;肥胖AUC 0.967/0.812)。
核心结论
- 非肥胖与肥胖NAFLD患者表现出独特的循环脂质组学特征,包括二酰甘油、三酰甘油和鞘磷脂。
- 这些脂质组合可能作为非肥胖和肥胖NAFLD患者的有用生物标志物。
研究设计与样本
- 横断面分析纳入361例经活检证实的NAFLD患者(157例NAFL和138例NASH)及66名健康对照,按亚洲体重指数切点分为肥胖与非肥胖。
- 基于NAFLD组织学严重程度进行血清循环脂质组学分析,并在独立验证集(154例NAFLD患者[93例NAFL和61例NASH]及21名健康对照)中验证循环脂质组学改变。
主要发现
- 饱和鞘磷脂(SM)种类与非肥胖NAFLD患者的内脏脂肪堆积显著相关(SM d38:0;P < 0.001),但在肥胖NAFLD中无此关联。
- SM水平与全身及脂肪组织胰岛素抵抗显著相关(SM d38:0;P = 0.002和<0.001)。
- 分别选出5种(非肥胖)和7种(肥胖)潜在脂质代谢物预测NAFLD和NASH,这些脂质组合在非肥胖(NAFLD/NASH的AUC = 0.916/0.813)和肥胖(NAFLD/NASH的AUC = 0.967/0.812)受试者中显示出良好的诊断性能。
- 验证集中确认了二酰甘油、三酰甘油和SM水平的不同改变模式,取决于NAFLD的组织学严重程度。
关键数值与推荐
- 非肥胖NAFLD中,SM d38:0与内脏脂肪堆积显著相关(P < 0.001)。
- SM d38:0与全身胰岛素抵抗显著相关(P = 0.002),与脂肪组织胰岛素抵抗显著相关(P < 0.001)。
- 非肥胖受试者中,脂质组合预测NAFLD的AUC为0.916,预测NASH的AUC为0.813。
- 肥胖受试者中,脂质组合预测NAFLD的AUC为0.967,预测NASH的AUC为0.812。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) affects obese and non-obese individuals. However, mechanisms underlying non-obese non-alcoholic steatohepatitis (NASH) remain unclear. AIMS: To attempt to identify metabolic perturbations associated with non-obese and obese NAFLD using a lipidomics approach. METHODS: A cross-sectional analysis of 361 subjects with biopsy-proven NAFLD (157 NAFL and 138 NASH) and healthy controls (n = 66) was performed. Individuals were categorised as obese or non-obese based on the Asian cut-off for body mass index. Circulating lipidomic profiling of sera was performed based on the histological severity of NAFLD. Circulating lipidomic alterations were validated with an independent validation set (154 NAFLD subjects [93 NAFL and 61 NASH] and 21 healthy controls). RESULTS: Saturated sphingomyelin (SM) species were significantly associated with visceral adiposity in non-obese NAFLD (SM d38:0; P < 0.001) but not in obese NAFLD. Additionally, SM levels were significantly associated with systemic and adipose tissue insulin resistance (SM d38:0; P = 0.002 and <0.001, respectively). Five potential lipid metabolites for non-obese subjects and seven potential lipids for obese subjects were selected to predict NAFLD and NASH. These lipid combinations showed good diagnostic performance for non-obese (area under the curve [AUC] for NAFLD/NASH = 0.916/0.813) and obese (AUC for NAFLD/NASH = 0.967/0.812) subjects. Moreover, distinctly altered patterns of diacylglycerol (DAG), triacylglycerol (TAG) and SM levels were confirmed in the validation set depending on the histological severity of NAFLD. CONCLUSION: Non-obese and obese NAFLD subjects exhibit unique circulating lipidomic signatures, including DAGs, TAGs and SMs. These lipid combinations may be useful biomarkers for non-obese and obese NAFLD patients.
引用
- Jung Y, Lee MK, Puri P, et al. Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020. PMID: 32892365. doi:10.1111/apt.16066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。